Primary Outcome Measures
Recommended phase II dose of the combination of Alectinib and Bevacizumab [Time Frame: 21 Days] [Designated as safety issue: ]
Number of participants treated with the combination of alectinib and bevacizumab with adverse events [Time Frame: 2 years] [Designated as safety issue: ]
Secondary Outcome Measures
Central nervous system objective response rate [Time Frame: 2 years] [Designated as safety issue: ]
Central nervous system disease control rate [Time Frame: 2 years] [Designated as safety issue: ]
Central nervous system progression-free survival [Time Frame: 2 years] [Designated as safety issue: ]
Overall objective response rate [Time Frame: 2 years] [Designated as safety issue: ]
Overall disease control rate [Time Frame: 2 years] [Designated as safety issue: ]
Progression-free survival [Time Frame: 2 years] [Designated as safety issue: ]
Quality of life: change from baseline to on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 [Time Frame: 2 years] [Designated as safety issue: ]
Quality of life: change from baseline and on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-BN20 [Time Frame: 2 years] [Designated as safety issue: ]
Number of patients with an ALK resistance mutation [Time Frame: 2 years] [Designated as safety issue: ]